跳至主要内容
临床试验/CTRI/2024/05/067430
CTRI/2024/05/067430尚未招募3 期

Role of neoadjuvant intravesical mitomycin C (MMC) treatment in patients with recurrent non-muscle invasive bladder cancer (NMIBC): A randomized controlled trial. - NI

AIIMS bhubaneswar0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • All patients with recurrent NMIBC

排除标准

  • 1) Non-UC of the bladder
  • 2) T2 and above tumours
  • 3) Suspicion or presence of CIS
  • 4) Pregnancy
  • 5) Urinary incontinence
  • 6) MIBC or benign disease
  • 7) Variant histology
  • 8) Prior intravesical MMC instillation for NMIBC within 3 y (intravesical MMC instillation within 3 y prior to study entry)
  • 9)Prior hypersensitivity reaction history to MMC
  • 10) Prior BCG treatment within the past 24 months
  • 11) Neurogenic bladder
  • 12) Untreated urinary tract infection
  • 13) Prior systemic chemotherapy for any malignancy within 6 months
  • 14) Any factors that would preclude study participation.
  • 15) Withdrawal of consent at any time during the clinical trial
  • No outpatient follow-up examination within 3 mo-1 y after TURBT
  • Failed intravesical MMC instillation before TURBT even once due to some reasons
  • Not eligible single intravesical chemotherapy instillation immediately after TURBT

研究者

相似试验